EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Evaluation, in a highly specialised enzyme laboratory, of a digital microfluidics platform for rapid assessment of lysosomal enzyme activity in dried blood spots

Rohit Hirachan, Alistair Horman, Derek Burke, Simon Heales iD

JIMD Reports · 2024-03 · 65 (2) · 124-131

DOI: 10.1002/jmd2.12413 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JIMD Reports, online erschienen am 19.02.2024. Verfasst von Rohit Hirachan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Chemical Pathology Camelia Botnar Laboratories, Great Ormond Street Hospital for Children NHS Foundation Trust London UK. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lysosomal storage disorders (LSDs) are predominantly enzyme deficiencies leading to substrate accumulation, causing progressive damage to multiple organs. To date, a crucial part of diagnosing LSDs is measuring enzymatic activity in leucocytes, plasma, or dried blood spots (DBS). Here, we present results from a proof‐of‐principle study, evaluating an innovative digital microfluidics (DMF) platform, referred to as SEEKER®, that can measure the activity of the following four lysosomal enzymes from DBS: α‐L‐iduronidase (IDUA) for mucopolysaccharidosis I (MPS I), acid α‐glucosidase (GAA) for Pompe disease, β‐glucosidase (GBA) for Gaucher disease, and α‐galactosidase A (GLA) for Fabry disease. Over 900 DBS were analysed from newborns, children, and adults. DMF successfully detected known patients with MPS I, Pompe disease, and Gaucher disease, and known males with Fabry disease. This is the first demonstration of this multiplexed DMF platform for identification of patients with LSDs in a specialised diagnostic enzyme laboratory environment. We conclude that this DMF platform is relatively simple, high‐throughput, and could be readily accommodated into a specialised laboratory as a first‐tier test for MPS I, Pompe disease, and Gaucher disease for all patients, and Fabry disease for male patients only.

Schlagwörter

Stichwörter der Autor:innen

Fabry diseaseGaucher diseasePompe diseasedigital microfluidicsdried blood spotlysosomal storage disordersmucopolysaccharidosis I

Autor:innen und Institutionen

  • Chemical Pathology Camelia Botnar Laboratories, Great Ormond Street Hospital for Children NHS Foundation Trust London UK.
  • Neurometabolic Unit National Hospital for Neurology and Neurosurgery London UK.

ORCID-Profile: Simon Heales

Zitieren

APA

Hirachan, R., Horman, A., Burke, D., & Heales, S. (2024). Evaluation, in a highly specialised enzyme laboratory, of a digital microfluidics platform for rapid assessment of lysosomal enzyme activity in dried blood spots. JIMD Reports, 65(2), 124-131. https://doi.org/10.1002/jmd2.12413

Vancouver

Hirachan R, Horman A, Burke D, Heales S. Evaluation, in a highly specialised enzyme laboratory, of a digital microfluidics platform for rapid assessment of lysosomal enzyme activity in dried blood spots. JIMD Reports. 2024;65(2):124-131. doi:10.1002/jmd2.12413

BibTeX
@article{Hirachan2024,
  author = {Hirachan, Rohit and Horman, Alistair and Burke, Derek and Heales, Simon},
  title = {Evaluation, in a highly specialised enzyme laboratory, of a digital microfluidics platform for rapid assessment of lysosomal enzyme activity in dried blood spots},
  journal = {JIMD Reports},
  year = {2024},
  volume = {65},
  number = {2},
  pages = {124--131},
  doi = {10.1002/jmd2.12413}
}
Kostenlos starten →